Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab in metastatic HER2-positive breast cancer
NCT06435429Phase 3Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Aug 2024
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of zanidatamab in HER2-positive breast cancer, sponsored by Jazz Pharmaceuticals plc. Started Aug 2024; status: recruiting.
02
Drugs
zanidatamab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06435429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435429.